Catalys Pacific — Full Portfolio
10 tracked investments · listed companies and verified rows first
Clinical-stage biopharmaceutical company committed to developing best-in-class novel therapy for hypertension treatment.
BiotechRadnor, US
Adam Levy(Executive Officer)Srinivas Akkaraju(Director)Alexander Asam(Director)
BoardOlivier Litzka(Director)Derek DiRocco(Director)
Board seatTakeshi TakahashiBrian Taylor Slingsby· per SEC Form D · $118M raise · filed Jun 2022
Company advancing treatments for patients with acid-related disorders
Hepalys Pharma is a late-stage biopharmaceutical company developing innovative therapeutics for liver disease in Japanese and Asian patients, focusing on metabolic dysfunction-associated steatohepatitis (MASH) treatment through its lead candidate Lanifibranor.
BiotechMedical DevicesTokyo, JP
Catalys Pacific
BiotechSan Diego, US
Eckard Weber, M.D.(Director)Michael Sanders(Executive Officer)Nicole Vitullo(Director)Dennis Podlesak(Executive Officer, Director)Rick Orr(Director)Lynne Rollins(Executive Officer)
Board seatTakeshi TakahashiBrian Taylor Slingsby· per SEC Form D · $25M raise · filed Apr 2020
Company addressing social issues in neurology (noted as acquired).
Arialys Therapeutics develops precision medicines targeting pathogenic autoantibodies in the brain to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechDigital HealthMedical DevicesLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)Ashish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
A multi-asset precision oncology company
A targeted approach for the control of hypertension
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.